$MTW

MANITOWOC CO INC SEC 10-K Report

The Manitowoc Company, Inc. (MTW) has released its 2025 Form 10-K report, detailing its financial performance, business operations, and strategic initiatives. The report highlights increased net sales and gross profit, though net income and diluted EPS decreased due to income tax provisions. Manitowoc is pursuing a "CRANES+50" strategy, focusing on non-new machine sales and aftermarket services, while navigating market competition, macroeconomic challenges, and supply chain risks.

Original reporting
Published Feb 19, 2026, 2:57 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Feb 19, 2026, 3:31 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
MANITOWOC CO INC SEC 10-K Report — source image
Decision brief

The 30-second read

$MTWNeutralMed
01

Why it matters

The company's focus on non-new machine sales could stabilize revenue streams but may limit growth compared to new equipment sales.

02

Market read

The news is relevant for investors and traders interested in industrial manufacturing and construction sectors, with moderate impact on MTW stock price.

03

What to watch

Potential supply chain disruptions or macroeconomic headwinds could further impact profitability, which are not fully captured in the current analysis.

Relevance 6/10Timing: Moderate; quarterly earnings and strategic updates are upcoming catalysts.

Background

Manitowoc's 2025 Form 10-K report highlights strategic shifts amidst a challenging macroeconomic environment, emphasizing aftermarket growth.

Company-level read

Ticker impact

$MTWNeutralMedium confidence
Context

Primary focus due to the company's financial report and strategic initiatives.

Expected impact

Potential sideways movement with slight upward bias over the medium term, contingent on execution of strategic initiatives and macroeconomic stability.

Evidence & confidence

The mixed financial results and strategic focus suggest a cautious outlook. The positive sales trend supports modest appreciation, but profit declines and macro risks temper optimism.

Market effects

The industrial manufacturing and construction sectors may experience slight positive sentiment due to Manitowoc's strategic focus on aftermarket services.

Primarily affects North American markets where Manitowoc has significant operations.

Limited; company-specific news with minimal immediate global impact.

Counterpoint

The decrease in net income and EPS may signal underlying operational issues, suggesting caution or potential short opportunities.

Key entities

  • Manitowoc Company, Inc.

    A manufacturer of cranes and related equipment.

Related articles

$MTWHighAI 9/10

Manitowoc (MTW) Q2 2026 Earnings Call Transcript

Manitowoc (MTW) reported Q2 2026 net sales of $594.9 million, up 10.3%, and adjusted EBITDA of $48.9 million, up 85.9%, with margin at 8.2%. Orders rose 56.1% to $708.7 million and backlog was $1,050.1 million. Full-year 2026 guidance was raised: net sales $2.3B-$2.4B and adjusted EBITDA $150M-$170M.

$MTWHighAI 9/10

Manitowoc Q2 Earnings Call Highlights

Manitowoc (NYSE:MTW) reported Q2 highlights including aftermarket non-new machine sales up 6% to $172 million, and trailing 12-month aftermarket sales of $706 million. July orders exceeded $200 million. The company cited tariff-related cash refunds of $26 million and raised 2026 guidance to net sales $2.3B-$2.4B and adjusted EBITDA $150M-$170M. Cash was $96M; liquidity $304M.

$MTWHigh

The Manitowoc Company Reports Strong Second-Quarter 2026 Results; Backlog Over $1.0 Billion, Adjusted EBITDA Improved 85.9% From the Prior Year, and Full…

MANITOWOC CO INC (MTW) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 The Manitowoc Company Reports Strong Second-Quarter 2026 Results; Backlog Over $1.0 Billion, Adjusted EBITDA Improved 85.9% From the Prior Year, and Full Year Guidance Raised Second-Quarter 2026 Highlights • Orders of $708.7 million, up 56.1% year-over-year. Backlog

$JNJMed

Johnson & Johnson announces ERLEADA® (apalutamide) treatment before and after surgery reduces risk of recurrence or death by 62% versus surgery alone in high-risk prostate cancer

Johnson & Johnson (JNJ) reported that a Phase 3 substudy of apalutamide plus ADT before and after surgery reduced the risk of recurrence or death by 62% in high-risk prostate cancer patients compared to surgery alone. The regimen also showed a 51% lower risk of metastasis or death. Results were presented at ESMO Congress 2026 and accepted for publication by European Urology.

$PBLSMedAI 9/10

Parabilis reports phase 1/2 data for desmoid tumor treatment

Parabilis Medicines (PBLS) reported phase 1/2 trial results for zolucatetide, showing a 72.2% response rate in 18 patients and 100% disease control in 46 patients. The company plans to start a phase 3 trial in 2027, with FDA alignment on study design and endpoints. Zolucatetide has Fast Track and Orphan Drug Designations for desmoid tumors.